Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance
Reference number: TA779
Published: 16 March 2022

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Published:

08 February 2022
Managed access agreement (PDF 370 KB)

Published:

08 February 2022
Equality Impact Assessment (Guidance development) (PDF 145 KB)

Published:

16 March 2022

Final draft guidance: 1

Final draft guidance: 1
Public committee slides (PDF 1.34 MB)

Published:

08 February 2022
Committee papers (PDF 6.08 MB)

Published:

08 February 2022
Final appraisal document (PDF 261 KB)

Published:

08 February 2022

Invitation to participate

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 319 KB)

Published:

16 March 2021
Final scope (PDF 186 KB)

Published:

16 March 2021
Final stakeholder list (PDF 161 KB)

Published:

16 March 2021
Equality impact assessment (Scoping) (PDF 124 KB)

Published:

16 March 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 177 KB)

Published:

12 October 2020
Draft matrix post referral (PDF 160 KB)

Published:

03 November 2020